<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">JYJkV4ddhMpXQzJMSD8Pmjp</article-id>
      <article-id pub-id-type="other">00008</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2009000700008</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(09)09300108</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2009000700008</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Valida&#231;&#227;o da vers&#227;o em portugu&#234;s do Minnesota Living with Heart Failure Questionnaire</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Carvalho</surname>
            <given-names>Vitor Oliveira</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Guimar&#227;es</surname>
            <given-names>Guilherme Veiga</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Carrara</surname>
            <given-names>Dirceu</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bacal</surname>
            <given-names>Fernando</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bocchi</surname>
            <given-names>Edimar Alcides</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade de S&#227;o Paulo</institution>
        <institution content-type="orgdiv1">Hospital das Clinicas </institution>
        <institution content-type="orgdiv2">Instituto do Cora&#231;&#227;o</institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>07</month>
        <year>2009</year>
      </pub-date>
      <volume>93</volume>
      <issue>1</issue>
      <fpage>39</fpage>
      <lpage>44</lpage>
      <history>
        <date date-type="received">
          <day>04</day>
          <month>06</month>
          <year>2008</year>
        </date>
        <date date-type="rev-recd">
          <day>08</day>
          <month>07</month>
          <year>2008</year>
        </date>
        <date date-type="accepted">
          <day>09</day>
          <month>07</month>
          <year>2008</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: O Minnesota Living with Heart Failure Questionnaire (MLHFQ) &#233; uma importante ferramenta de avalia&#231;&#227;o da qualidade de vida em pacientes com insufici&#234;ncia card&#237;aca. Apesar de amplamente usado em nosso meio, n&#227;o cont&#225;vamos com a sua tradu&#231;&#227;o e valida&#231;&#227;o em l&#237;ngua portuguesa. OBJETIVO: Este estudo pretendeu traduzir e validar a vers&#227;o em portugu&#234;s do MLHFQ em pacientes com insufici&#234;ncia card&#237;aca. M&#201;TODOS: Quarenta pacientes com insufici&#234;ncia card&#237;aca (30 homens, FEVE 30&#177;6%, 55% de etiologia isqu&#234;mica, NYHA I a III) com estabilidade cl&#237;nica e terapia medicamentosa otimizada realizaram teste cardiopulmonar m&#225;ximo para avalia&#231;&#227;o da capacidade f&#237;sica. Logo ap&#243;s, o MLHFQ, devidamente traduzido, foi aplicado por um mesmo pesquisador. A classe funcional NYHA foi encaminhada pela equipe medica. RESULTADOS: A vers&#227;o em portugu&#234;s do MLHFQ apresentou-se com a mesma estrutura e m&#233;trica da vers&#227;o original. N&#227;o houve dificuldade na aplica&#231;&#227;o e compreens&#227;o do question&#225;rio por parte dos pacientes. A vers&#227;o em portugu&#234;s do MLHFQ mostrou-se concordante com o pico de VO2, o tempo de exerc&#237;cio do teste cardiopulmonar e com a classifica&#231;&#227;o funcional da NYHA. N&#227;o houve diferen&#231;a da m&#233;dia do escore do question&#225;rio entre os grupos de etiologia isqu&#234;mica e n&#227;o-isqu&#234;mica. CONCLUS&#195;O: A vers&#227;o em l&#237;ngua portuguesa da MLHFQ, proposta no presente estudo, demonstrou ser v&#225;lida em pacientes com insufici&#234;ncia card&#237;aca, constituindo uma nova e importante ferramenta para avaliar a qualidade de</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Insufici&#234;ncia card&#237;aca</kwd>
        <kwd>valida&#231;&#227;o</kwd>
        <kwd>question&#225;rios</kwd>
        <kwd>qualidade de vida</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>13</day>
        <month>10</month>
        <year>2009</year>
      </pub-date>
    </article-meta>
  </front>
  <body><p>ARTIGO ORIGINAL </p><p> INSUFICI&#202;NCIA CARD&#205;ACA</p><p><bold>Valida&#231;&#227;o da vers&#227;o em portugu&#234;s do <italic>Minnesota Living with Heart Failure Questionnaire</italic></bold></p><p><bold>Vitor Oliveira Carvalho; Guilherme Veiga Guimar&#227;es; Dirceu Carrara; Fernando Bacal; Edimar Alcides Bocchi</bold></p><p>Laborat&#243;rio de Insufici&#234;ncia Card&#237;aca e Transplante do Instituto do Cora&#231;&#227;o do Hospital das Clinicas da Universidade de S&#227;o Paulo (InCor HCFMUSP), S&#227;o Paulo, SP - Brasil</p><p><xref ref-type="corresp" rid="back">Correspond&#234;ncia</xref></p><p><bold>RESUMO</bold></p><bold>FUNDAMENTO:</bold> O <italic> Minnesota Living with Heart Failure Questionnaire</italic> (MLHFQ) &#233; uma importante ferramenta de avalia&#231;&#227;o da qualidade de vida em pacientes com insufici&#234;ncia card&#237;aca. Apesar de amplamente usado em nosso meio, n&#227;o cont&#225;vamos com a sua tradu&#231;&#227;o e valida&#231;&#227;o em l&#237;ngua portuguesa. <p content-type="break"><bold>OBJETIVO:</bold> Este estudo pretendeu traduzir e validar a vers&#227;o em portugu&#234;s do MLHFQ em pacientes com insufici&#234;ncia card&#237;aca. </p><p content-type="break"><bold>M&#201;TODOS:</bold> Quarenta pacientes com insufici&#234;ncia card&#237;aca (30 homens, FEVE 30&#177;6%, 55% de etiologia isqu&#234;mica, NYHA I a III) com estabilidade cl&#237;nica e terapia medicamentosa otimizada realizaram teste cardiopulmonar m&#225;ximo para avalia&#231;&#227;o da capacidade f&#237;sica. Logo ap&#243;s, o MLHFQ, devidamente traduzido, foi aplicado por um mesmo pesquisador. A classe funcional NYHA foi encaminhada pela equipe medica. </p><p content-type="break"><bold>RESULTADOS:</bold> A vers&#227;o em portugu&#234;s do MLHFQ apresentou-se com a mesma estrutura e m&#233;trica da vers&#227;o original. N&#227;o houve dificuldade na aplica&#231;&#227;o e compreens&#227;o do question&#225;rio por parte dos pacientes. A vers&#227;o em portugu&#234;s do MLHFQ mostrou-se concordante com o pico de VO<sub>2</sub>, o tempo de exerc&#237;cio do teste cardiopulmonar e com a classifica&#231;&#227;o funcional da NYHA. N&#227;o houve diferen&#231;a da m&#233;dia do escore do question&#225;rio entre os grupos de etiologia isqu&#234;mica e n&#227;o-isqu&#234;mica. </p><p content-type="break"><bold>CONCLUS&#195;O: </bold>A vers&#227;o em l&#237;ngua portuguesa da MLHFQ, proposta no presente estudo, demonstrou ser v&#225;lida em pacientes com insufici&#234;ncia card&#237;aca, constituindo uma nova e importante ferramenta para avaliar a qualidade de vida.  </p><p><bold>Palavras-chave:</bold> Insufici&#234;ncia card&#237;aca, valida&#231;&#227;o, question&#225;rios, qualidade de vida.</p>     <p><bold>Introdu&#231;&#227;o</bold></p> <p>A insufici&#234;ncia card&#237;aca &#233; a via final comum de toda cardiopatia e &#233; caracterizada por atividade neuro-hormonal exacerbada, baixa toler&#226;ncia ao exerc&#237;cio, baixa sobrevida e qualidade de vida deteriorada<sup>1-3</sup>.</p> <p>Qualidade de vida &#233; uma discrep&#226;ncia entre satisfa&#231;&#227;o ou descontentamento com determinadas &#225;reas da vida, de acordo com a percep&#231;&#227;o do pr&#243;prio indiv&#237;duo, sendo essa percep&#231;&#227;o considerada o melhor indicador de qualidade de vida<sup>4</sup>. Na linguagem convencional, satisfa&#231;&#227;o com a vida refere-se ao cumprimento de necessidades, expectativas, anseios e desejos<sup>5</sup>.</p> <p>Ao trabalharmos com qualidade de vida estaremos avaliando o paciente nas dimens&#245;es &#237;ntima, interativa, social e f&#237;sica, ou seja, como a pessoa se comporta perante si mesma e o mundo que a cerca, levando em considera&#231;&#227;o as rela&#231;&#245;es interpessoais e como o mundo em que ela vive interfere em seu estado &#237;ntimo, f&#237;sico e social<sup>6</sup>.</p> <p>Existe o esfor&#231;o da comunidade cient&#237;fica em quantificar o impacto da insufici&#234;ncia card&#237;aca na vida dos pacientes. Apesar de haver a classifica&#231;&#227;o funcional da <italic>New York Heart Association</italic> (NYHA) e do teste de caminhada dos seis minutos<sup>7,8</sup>, criou-se o <italic>Minnesota Living with Heart Failure Questionnaire</italic> (MLHFQ) que hoje &#233; amplamente usado em nosso meio e no mundo. Apesar disso, n&#227;o houve a sua tradu&#231;&#227;o e valida&#231;&#227;o no Brasil.</p> <p>O objetivo deste estudo foi traduzir e validar a vers&#227;o brasileira do MLHFQ em pacientes com insufici&#234;ncia card&#237;aca.</p>   <p><bold>M&#233;todos</bold></p> <p><bold>Popula&#231;&#227;o</bold></p> <p>Quarenta pacientes com insufici&#234;ncia card&#237;aca (30 homens, fra&#231;&#227;o de eje&#231;&#227;o do ventr&#237;culo esquerdo 30&#177;6%) foram recrutados de um ambulat&#243;rio especializado em insufici&#234;ncia card&#237;aca de um hospital de alta complexidade em cardiologia, entre mar&#231;o de 2007 e mar&#231;o de 2008 (<xref ref-type="table" rid="t1">tab.1</xref>).</p> <table-wrap id="t1"><graphic xlink:href="1678-4170-abc-93-01-0039-00008-gt01.jpg"/></table-wrap>   <p>Todos os pacientes apresentavam estabilidade cl&#237;nica sem altera&#231;&#245;es nas medica&#231;&#245;es e sem per&#237;odos de interna&#231;&#227;o por tr&#234;s meses. Foram exclu&#237;dos do estudo pacientes com outras limita&#231;&#245;es funcionais al&#233;m da insufici&#234;ncia card&#237;aca, como osteoartrose importante, acidente vascular encef&#225;lico e doen&#231;a pulmonar obstrutiva cr&#244;nica.</p> <p>Previamente, os pacientes foram informados quanto &#224; finalidade do estudo e foi solicitada a aquiesc&#234;ncia com a assinatura do termo de consentimento aprovado pelo Comit&#234; de &#201;tica da institui&#231;&#227;o.</p> <p><bold>Din&#226;mica do estudo</bold></p> <p>Neste estudo transversal, todos os pacientes compareceram em nosso laborat&#243;rio, onde realizaram um teste cardiopulmonar m&#225;ximo para avalia&#231;&#227;o da capacidade f&#237;sica. Logo ap&#243;s, a vers&#227;o em portugu&#234;s do MLHFQ, devidamente traduzida, foi aplicada duas vezes com intervalo de uma semana por um mesmo pesquisador a fim de preservar a homogeneidade do padr&#227;o e interpreta&#231;&#227;o das respostas alcan&#231;adas e permitir melhor qualidade na exatid&#227;o dos dados obtidos. As classifica&#231;&#245;es funcionais pela NYHA foram encaminhadas pela equipe m&#233;dica do ambulat&#243;rio respons&#225;vel pelo paciente<sup>9</sup>.</p> <p><bold>Teste cardiopulmonar</bold></p> <p>Os pacientes foram orientados a n&#227;o realizar nenhuma atividade f&#237;sica cansativa e a n&#227;o ingerir caf&#233; ou &#225;lcool nas 24 horas que antecediam o exame. A &#250;ltima refei&#231;&#227;o foi feita, ao menos, duas horas antes do exame. Todos os pacientes realizaram o teste cardiopulmonar m&#225;ximo (protocolo de Naughton) em uma esteira rolante (Series 2000; <italic>Marquette Electronics</italic>; Milwaukee, WI, USA) em uma sala com temperatura controlada (21-23&#186;C) entre 10h00 e 15h00 com o registro eletrocardiogr&#225;fico de 12 deriva&#231;&#245;es (Max 1; <italic>Marquette Electronics</italic>; Milwaukee, WI, USA) e press&#227;o arterial medida pelo m&#233;todo auscultat&#243;rio. Ventila&#231;&#227;o (VE, BTPS), consumo de Oxig&#234;nio (VO<sub>2</sub>, STPD), g&#225;s carb&#244;nico (VCO<sub>2</sub>, STPD) e as outras vari&#225;veis cardiopulmonares foram adquiridas respira&#231;&#227;o a respira&#231;&#227;o por um sistema computadorizado (Vm&#225;x 229 model, <italic>SensorMedics</italic>, Yorba Linda, CA, USA). Considerou-se o pico do VO<sub>2</sub> como a m&#233;dia dos valores finais 30 segundos antes da exaust&#227;o. Um teste satisfat&#243;rio foi considerado pelo quociente respirat&#243;rio (R/Q) &gt;1,05 associado a sintomas de esfor&#231;o m&#225;ximo.</p> <p><bold>Tradu&#231;&#227;o para a l&#237;ngua portuguesa do <italic>Minnesota Living With Heart Failure Questionnaire</italic></bold></p> <p>Realizou-se a tradu&#231;&#227;o de acordo com algumas etapas propostas pelos coordenadores do IQOLA e, tamb&#233;m, com base em trabalhos da literatura que abordam a metodologia para a tradu&#231;&#227;o de question&#225;rios de avalia&#231;&#227;o de qualidade de vida para outras l&#237;nguas que n&#227;o a original.</p> <p><bold>Tradu&#231;&#227;o Inicial</bold></p> <p>Os itens da vers&#227;o original do MLHFQ inicialmente foram traduzidos para a l&#237;ngua portuguesa por dois professores de ingl&#234;s independentes, brasileiros, que estavam cientes dos objetivos desse trabalho. Nesse momento foi enfatizada, especialmente, a tradu&#231;&#227;o conceitual e n&#227;o a estritamente liter&#225;ria. As duas tradu&#231;&#245;es foram ent&#227;o comparadas pelos tradutores e o pesquisador e, em caso de diverg&#234;ncias, foram feitas modifica&#231;&#245;es para se obter um consenso quanto &#224; tradu&#231;&#227;o inicial (vers&#227;o n&#186; 1 em portugu&#234;s).</p> <p><bold>Avalia&#231;&#227;o da tradu&#231;&#227;o inicial</bold></p> <p>A tradu&#231;&#227;o inicial foi vertida para o ingl&#234;s por dois professores de ingl&#234;s, um de nacionalidade inglesa e outro, americana, que n&#227;o participaram da etapa anterior. Posteriormente, compararam-se essas duas vers&#245;es com o instrumento original em ingl&#234;s e as discrep&#226;ncias existentes foram documentadas e analisadas por um grupo composto de dois cardiologistas, um enfermeiro, um psic&#243;logo e um dos professores de ingl&#234;s. Quando necess&#225;rio, as senten&#231;as em portugu&#234;s foram reescritas at&#233; a obten&#231;&#227;o de um consenso, gerando-se a vers&#227;o n&#186; 2 em portugu&#234;s.</p> <p><bold>An&#225;lise estat&#237;stica</bold></p> <p>Os dados foram analisados com o programa estat&#237;stico SPSS vers&#227;o 11,5 (SPSS Inc., Chicago, IL, USA). A an&#225;lise descritiva foi apresentada em m&#233;dia e desvio padr&#227;o. O coeficiente de correla&#231;&#227;o intraclasse (r<sub>i</sub>) com 95% de intervalo de confian&#231;a foi usado para testar a concord&#226;ncia da aplica&#231;&#227;o e reaplica&#231;&#227;o do QQVM (Question&#225;rio de Qualidade de vida de Minnesota). Adicionalmente, foi realizada uma avalia&#231;&#227;o visual por meio do gr&#225;fico de Bland &amp; Altman com o limite de 95% de concord&#226;ncia. A consist&#234;ncia interna da escala foi avaliada por meio do coeficiente alfa de Cronbach. A validade da QQVM em compara&#231;&#227;o ao pico VO<sub>2</sub>, tempo de exerc&#237;cio no teste cardiopulmonar e a classifica&#231;&#227;o funcional da NYHA foi avaliada por meio do coeficiente de correla&#231;&#227;o de Spearman. O teste "t" de Student n&#227;o-pareado foi usado para comparar as m&#233;dias do escore do QQVM entre os grupos de etiologia isqu&#234;mica e n&#227;o-isqu&#234;mica.</p>   <p><bold>Resultados</bold></p> <p>Os pacientes inclu&#237;dos neste estudo apresentaram uma capacidade f&#237;sica deteriorada (pico de VO<sub>2</sub> menor que 20 mL.Kg.min), um comprometimento funcional da NYHA consider&#225;vel e um escore da vers&#227;o em portugu&#234;s do MLHFQ (isto &#233;, Question&#225;rio de Qualidade de vida de Minnesota - QQVM) elevado (<xref ref-type="table" rid="t1">tab.1</xref>). N&#227;o houve diferen&#231;a no escore do QQVM para o grupo isqu&#234;mico e para o grupo n&#227;o-isqu&#234;mico (53&#177;15 e 42&#177;19, respectivamente; p=0,57; IC= - 4.5212 a 27.1640).</p> <p>A vers&#227;o em portugu&#234;s do MLHFQ apresentou-se com a mesma estrutura e m&#233;trica da vers&#227;o original (<xref ref-type="app" rid="a1">anexo 1</xref>). O QQVM mostrou-se concordante entre a aplica&#231;&#227;o e reaplica&#231;&#227;o do question&#225;rio (r<sub>i</sub>=0,97; p&lt;0,0001) (<xref ref-type="fig" rid="f1">figura 1</xref>). O coeficiente alfa de Cronbach foi de 0,97.</p> <fig id="f1"><graphic xlink:href="1678-4170-abc-93-01-0039-00008-gf01.jpg"/></fig>   <p>Foram observadas correla&#231;&#245;es significativas do escore total do QQVM com o pico de VO<sub>2</sub>, o tempo de exerc&#237;cio do teste cardiopulmonar e com a classifica&#231;&#227;o funcional da NYHA (<xref ref-type="table" rid="t2">tabela2</xref>).</p> <table-wrap id="t2"><graphic xlink:href="1678-4170-abc-93-01-0039-00008-gt02.jpg"/></table-wrap>   <p><bold>Discuss&#227;o</bold></p> <p>O presente estudo efetuou a tradu&#231;&#227;o do MLHFQ para a l&#237;ngua portuguesa. Al&#233;m disso, essa vers&#227;o foi concordante com a classifica&#231;&#227;o funcional da NYHA, pico de VO<sub>2</sub> e tempo de exerc&#237;cio durante o teste cardiopulmonar de pacientes com insufici&#234;ncia card&#237;aca. N&#227;o Houve dificuldade na aplica&#231;&#227;o da vers&#227;o em portugu&#234;s do MLHFQ por parte do pesquisador, nem no entendimento do mesmo pelos pacientes envolvidos neste estudo.</p> <p>O MLHFQ &#233; composto por 21 quest&#245;es relativas a limita&#231;&#245;es que frequentemente est&#227;o associadas com o quanto a insufici&#234;ncia card&#237;aca impede os pacientes de viverem como gostariam. Deve-se considerar o &#250;ltimo m&#234;s para responder aos questionamentos. A escala de respostas para cada quest&#227;o varia de 0 (n&#227;o) a 5 (demais), onde o 0 representa sem limita&#231;&#245;es e o 5, limita&#231;&#227;o m&#225;xima. Essas quest&#245;es envolvem uma dimens&#227;o f&#237;sica (de 1 a 7, 12 e 13) que est&#227;o altamente inter-relacionadas com dispn&#233;ia e fadiga, uma dimens&#227;o emocional (de 17 a 21) e outras quest&#245;es (de n&#250;mero 8, 9, 10, 11, 14, 15 e 16) que, somadas &#224;s dimens&#245;es anteriores, formam o escore total. Esse subgrupo de quest&#245;es, por n&#227;o possuir um padr&#227;o usual de respostas, n&#227;o foi agrupado como uma dimens&#227;o separada no question&#225;rio<sup>10</sup>.</p> <p>O MLHFQ foi desenvolvido especificamente para insufici&#234;ncia card&#237;aca, o que o torna mais pr&#243;ximo &#224; realidade desse tipo de paciente. Por isso, esse question&#225;rio pode divergir em algumas quest&#245;es quando comparado com outros gen&#233;ricos, como o 36-item <italic>Short-Form Health Survey</italic> (SF-36) desenvolvido para doen&#231;a cr&#244;nica<sup>11,12</sup>. Apesar disso, mostrou-se boa concord&#226;ncia entre o QQVM com o SF-36 em estudo pr&#233;vio, por&#233;m nenhum dado de capacidade f&#237;sica foi investigado<sup>12</sup>.</p> <p>&#201; sabido que a classifica&#231;&#227;o funcional da NYHA &#233; delimitada pela gravidade dos sintomas da insufici&#234;ncia card&#237;aca e, por esse motivo, esperava-se que o MLHFQ fosse &#250;til na discrimina&#231;&#227;o de pacientes com diversos n&#237;veis de gravidade. Apesar disso, essa hip&#243;tese n&#227;o foi confirmada<sup>12</sup>. Em nosso estudo, a classifica&#231;&#227;o funcional da NYHA fornecido pela equipe m&#233;dica, assim como o VO<sub>2</sub> de pico e o tempo do teste cardiopulmonar mostraram-se concordante com o escore do QQVM. Um estudo espanhol obteve uma forte correla&#231;&#227;o entre classe funcional da NYHA com o escore da vers&#227;o espanhola do MLHFQ, o que levou os autores a conclu&#237;rem que o MLHFQ pode refletir a gravidade da insufici&#234;ncia card&#237;aca<sup>13</sup>. Nosso estudo obteve o mesmo resultado. Esse dado nos leva a imaginar que a vers&#227;o em portugu&#234;s do MLHFQ tamb&#233;m possa refletir a gravidade da insufici&#234;ncia card&#237;aca. Apesar de a etiologia apresentar um car&#225;ter progn&#243;stico na insufici&#234;ncia card&#237;aca<sup>14</sup>, n&#227;o encontramos diferen&#231;a no QQVM entre os grupos de etiologia isqu&#234;mica e n&#227;o-isqu&#234;mica.</p> <p>O MLHFQ pode ser usado de forma &#250;nica para acessar a qualidade de vida dos pacientes com insufici&#234;ncia card&#237;aca ou para avaliar o efeito de uma interven&#231;&#227;o. Pela grande import&#226;ncia do MLHFQ, v&#225;rios estudos realizados no Brasil usaram o MLHFQ mesmo sem a sua devida tradu&#231;&#227;o, valida&#231;&#227;o e publica&#231;&#227;o. Bocchi e cols.<sup>15</sup> estudaram a qualidade de vida pelo escore de Minnesota em pacientes com Insufici&#234;ncia card&#237;aca em uso de levosimendana. Issa e cols.<sup>16</sup> estudaram o efeito do Bisoprolol na qualidade de vida, e Vilas-Boas e cols.<sup>17</sup>, o transplante de c&#233;lulas de medula &#243;ssea para o mioc&#225;rdio de pacientes com insufici&#234;ncia card&#237;aca de etiologia chag&#225;sica.</p> <p><bold>Limita&#231;&#245;es do estudo</bold></p> <p>Este estudo foi limitado pela n&#227;o-aplica&#231;&#227;o de um question&#225;rio de qualidade de vida validado no Brasil, como o SF-36. Essa compara&#231;&#227;o, no entanto, j&#225; foi realizada previamente<sup>12</sup>.</p>   <p><bold>Conclus&#227;o</bold></p> <p>A vers&#227;o em l&#237;ngua portuguesa da MLHFQ, proposta no presente estudo, demonstrou ser v&#225;lida em pacientes com insufici&#234;ncia card&#237;aca, constituindo uma nova e importante ferramenta para avaliar a qualidade de vida e a limita&#231;&#227;o na capacidade de realizar atividades da vida di&#225;ria nessa popula&#231;&#227;o.</p> <p><bold>Potencial Conflito de Interesses</bold></p> <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p> <p><bold>Fontes de Financiamento</bold></p> <p>O presente estudo foi parcialmente financiado pela CAPES.</p> <p><bold>Vincula&#231;&#227;o Acad&#234;mica</bold></p> <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>                         <p><fn id="back" fn-type="corresp"><label><bold> Correspond&#234;ncia:</bold></label><p>Vitor Oliveira Carvalho  </p><p>Av. Dr. En&#233;as de Carvalho Aguiar, 44 </p><p> Laborat&#243;rio de Insufici&#234;ncia Card&#237;aca e Transplante - Bloco 1, 10 Andar </p><p> 05403-900 - S&#227;o Paulo, SP - Brasil </p><p>E-mail: : </p><p><email xlink:href="vitor.carvalho@usp.br">vitor.carvalho@usp.br</email></p></fn></p> <p>Artigo recebido em 04/06/2008; revisado recebido em 08/07/2008; aceito em 09/07/2008.</p>     <p><italic><bold>Minnesota Living with Heart Failure Questionnaire</bold></italic> (Tradu&#231;&#227;o para o Portugu&#234;s)</p>   <p><graphic xlink:href="1678-4170-abc-93-01-0039-00008-e01.jpg"/></p></body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Chizzola PR,    Gon&#231;alves de Freitas HF, Marinho NV, Mansur JA, Meneghetti JC, Bocchi    EA. The effect of beta-adrenergic receptor antagonism in cardiac sympathetic    neuronal remodeling in patients with heart failure. Int J Cardiol. 2006;106    (1): 29-34.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The effect of beta-adrenergic receptor antagonism in cardiac sympathetic neuronal remodeling in patients with heart failure</article-title>
          <source>Int J Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>29</fpage>
          <lpage>34</lpage>
          <issue>1</issue>
          <volume>106</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Chizzola</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Gon&#231;alves de Freitas</surname>
              <given-names>HF</given-names>
            </name>
            <name>
              <surname>Marinho</surname>
              <given-names>NV</given-names>
            </name>
            <name>
              <surname>Mansur</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Meneghetti</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Bocchi</surname>
              <given-names>EA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Bocchi EA, Vilas-Boas    F, Perrone S, Caama&#241;o AG, Clausell N, Moreira Mda C, et al. I Latin American    Guidelines for the Assessment and Management of Decompensated Heart Failure.    Arq Bras Cardiol. 2005; 85 (supl 3): 49-94; 1-48.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>I Latin American Guidelines for the Assessment and Management of Decompensated Heart Failure</article-title>
          <source>Arq Bras Cardiol.</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>49</fpage>
          <lpage>94</lpage>
          <volume>85</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bocchi</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Vilas-Boas</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Perrone</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Caama&#241;o</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Clausell</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Moreira Mda</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Bocchi EA. Situa&#231;&#227;o    atual das indica&#231;&#245;es e resultados do tratamento cir&#250;rgico    da insufici&#234;ncia card&#237;aca. Arq Bras Cardiol. 1994; 63: 523-30.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Situa&#231;&#227;o atual das indica&#231;&#245;es e resultados do tratamento cir&#250;rgico da insufici&#234;ncia card&#237;aca</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>523</fpage>
          <lpage>30</lpage>
          <volume>63</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bocchi</surname>
              <given-names>EA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Ferrans CE,    Powers MJ. Psychometric assessment of the quality of life index. Res Nurs Health.    1992; 15: 29-38.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Psychometric assessment of the quality of life index</article-title>
          <source>Res Nurs Health</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>29</fpage>
          <lpage>38</lpage>
          <volume>15</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ferrans</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Powers</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. George LF, Bearron    LB. Quality of life in older persons: meaning and measurement. New York: Human    Sciences Press; 1980.</mixed-citation>
        <element-citation publication-type="book">
          <source>Quality of life in older persons: meaning and measurement</source>
          <date>
            <year>1980</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>George</surname>
              <given-names>LF</given-names>
            </name>
            <name>
              <surname>Bearron</surname>
              <given-names>LB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Pilon AF. Qualidade    de vida e formas de relacionamento homem/mundo. Rev Bras Sa&#250;de Esc. 1992;    2 (3): 117-25.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Qualidade de vida e formas de relacionamento homem/mundo</article-title>
          <source>Rev Bras Sa&#250;de Esc</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>117</fpage>
          <lpage>25</lpage>
          <issue>3</issue>
          <volume>2</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pilon</surname>
              <given-names>AF</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Guimar&#227;es    GV, Carvalho VO, Bocchi EA. Reproducibility of the self-controlled six-minute    walking test in heart failure patients. Clinics. 2008; 63 (2): 201-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Reproducibility of the self-controlled six-minute walking test in heart failure patients</article-title>
          <source>Clinics</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>201</fpage>
          <lpage>6</lpage>
          <issue>2</issue>
          <volume>63</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Guimar&#227;es</surname>
              <given-names>GV</given-names>
            </name>
            <name>
              <surname>Carvalho</surname>
              <given-names>VO</given-names>
            </name>
            <name>
              <surname>Bocchi</surname>
              <given-names>EA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Guimar&#227;es    GV, Bellotti G, Bacal F, Mocelin A, Bocchi EA. Can the cardiopulmonary 6-minute    walk test reproduce the usual activities of patients with heart failure? Arq    Bras Cardiol. 2002; 78 (6): 553-60.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Can the cardiopulmonary 6-minute walk test reproduce the usual activities of patients with heart failure?</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>553</fpage>
          <lpage>60</lpage>
          <issue>6</issue>
          <volume>78</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Guimar&#227;es</surname>
              <given-names>GV</given-names>
            </name>
            <name>
              <surname>Bellotti</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bacal</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Mocelin</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bocchi</surname>
              <given-names>EA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <mixed-citation>9. The Criteria Committee of the New York Heart Association Nomenclature and Criteria for Diagnosis of the Heart and Great Vessels. 9th ed. Boston: Little Brown; 1994.</mixed-citation>
        <element-citation publication-type="book">
          <source>The Criteria Committee of the New York Heart Association Nomenclature and Criteria for Diagnosis of the Heart and Great Vessels</source>
          <date>
            <year>1994</year>
          </date>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Rector TS,    Cohn JN. Assessment of patient outcome with the Minnesota Living With Heart    Failure Questionnaire: reliability and validity during a randomized, double-blind,    placebo-controlled trial of pimobendan. Am Heart J. 1992; 124: 1017-25.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Assessment of patient outcome with the Minnesota Living With Heart Failure Questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan</article-title>
          <source>Am Heart J</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>1017</fpage>
          <lpage>25</lpage>
          <volume>124</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rector</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Cohn</surname>
              <given-names>JN</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Garin O, Soriano    N, Ribera A, Ferrer M, Pont A, Alonso J, et al. Validaci&#243;n de la versi&#243;n    espa&#241;ola del Minnesota Living with Heart Failure Questionnaire. Rev Esp    Cardiol. 2008; 61 (3): 251-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Validaci&#243;n de la versi&#243;n espa&#241;ola del Minnesota Living with Heart Failure Questionnaire</article-title>
          <source>Rev Esp Cardiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>251</fpage>
          <lpage>9</lpage>
          <issue>3</issue>
          <volume>61</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Garin</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Soriano</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ribera</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ferrer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pont</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Alonso</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Saccomann I,    Cintra F, Gallani M. Psychometric properties of the Minnesota Living with Heart    Failure-Brazilian version-in the elderly. Qual Life Res. 2007; 16: 997-1005.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Psychometric properties of the Minnesota Living with Heart Failure-Brazilian version-in the elderly</article-title>
          <source>Qual Life Res</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>997</fpage>
          <lpage>1005</lpage>
          <volume>16</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Saccomann</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Cintra</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Gallani</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Paraj&#243;n    T, Lup&#243;n J, Gonz&#225;lez B, Urrutia A, Altimir S, Coll R. Use of the    Minnesota Living With Heart Failure Quality of Life Questionnaire in Spain.    Rev Esp Cardiol. 2004; 57 (2): 155-60.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Use of the Minnesota Living With Heart Failure Quality of Life Questionnaire in Spain</article-title>
          <source>Rev Esp Cardiol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>155</fpage>
          <lpage>60</lpage>
          <issue>2</issue>
          <volume>57</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Paraj&#243;n</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Lup&#243;n</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gonz&#225;lez</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Urrutia</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Altimir</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Coll</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Rassi S, Barretto    AC, Porto CC, Pereira CR, Cala&#231;a BW, Rassi DC. Survival and prognostic    factors in systolic heart failure with recent symptom onset. Arq Bras Cardiol.    2005; 84 (4): 309-13.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Survival and prognostic factors in systolic heart failure with recent symptom onset</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>309</fpage>
          <lpage>13</lpage>
          <issue>4</issue>
          <volume>84</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rassi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Barretto</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Porto</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Cala&#231;a</surname>
              <given-names>BW</given-names>
            </name>
            <name>
              <surname>Rassi</surname>
              <given-names>DC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Bocchi EA,    Vilas-Boas F, Moreira MC, Barretto AC, Lage S, Albuquerque D, Investigators    of Belief Study: Heart Failure Working Group of Brazilian Society of Cardiology.    Levosimendan in decompensated heart failure patients: efficacy in a Brazilian    cohort. Results of the BELIEF study. Arq Bras Cardiol. 2008; 90 (3): 182-90.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Investigators of Belief Study: Heart Failure Working Group of Brazilian Society of Cardiology. Levosimendan in decompensated heart failure patients efficacy in a Brazilian cohort. Results of the BELIEF study</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>182</fpage>
          <lpage>90</lpage>
          <issue>3</issue>
          <volume>90</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bocchi</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Vilas-Boas</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Moreira</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Barretto</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Lage</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Albuquerque</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Issa VS, Guimar&#227;es    GV, Rezende MV, Cruz FD, Ferreira SM, Bacal F, et al. Effects of bisoprolol    on cardiac function and exercise in patients with heart failure. Arq Bras Cardiol.    2007; 88 (3): 340-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effects of bisoprolol on cardiac function and exercise in patients with heart failure</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>340</fpage>
          <lpage>5</lpage>
          <issue>3</issue>
          <volume>88</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Issa</surname>
              <given-names>VS</given-names>
            </name>
            <name>
              <surname>Guimar&#227;es</surname>
              <given-names>GV</given-names>
            </name>
            <name>
              <surname>Rezende</surname>
              <given-names>MV</given-names>
            </name>
            <name>
              <surname>Cruz</surname>
              <given-names>FD</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Bacal</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Vilas-Boas    F, Feitosa GS, Soares MB, Mota A, Pinho-Filho JA, Almeida AJ. Early results    of bone marrow cell transplantation to the myocardium of patients with heart    failure due to Chagas disease. Arq Bras Cardiol. 2006; 87 (2): 159-66.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Early results of bone marrow cell transplantation to the myocardium of patients with heart failure due to Chagas disease</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>159</fpage>
          <lpage>66</lpage>
          <issue>2</issue>
          <volume>87</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Vilas-Boas</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Feitosa</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Soares</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Mota</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pinho-Filho</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
    <app-group>
      <app id="a1">
        <label>Anexo 1</label>
        <title> - </title>
      </app>
    </app-group>
  </back>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Validaci&#243;n de la versi&#243;n en portugu&#233;s del Minnesota Living with Heart Failure Questionnaire</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: El Minnesota Living with Heart Failure Questionnaire (MLHFQ) es un importante instrumento de evaluaci&#243;n de la calidad de vida en pacientes con insuficiencia cardiaca. A pesar de su amplio empleo en nuestro medio, no cont&#225;bamos con su traducci&#243;n y validaci&#243;n en lengua portuguesa. OBJETIVO: Este estudio tuvo por objeto traducir y validar la versi&#243;n en portugu&#233;s del MLHFQ en pacientes con insuficiencia cardiaca. M&#201;TODOS: Se realiz&#243; la prueba de ejercicio cardiopulmonar m&#225;ximo en 40 pacientes con insuficiencia cardiaca (30 varones, FEVE 30&#177;6%, el 55% de etiolog&#237;a isqu&#233;mica, NYHA I a III) con estabilidad cl&#237;nica y terapia medicamentosa optimizada, para evaluarse la capacidad f&#237;sica. Acto seguido, un investigador aplic&#243; el MLHFQ debidamente traducido. La clase funcional NYHA fue referida por el equipo m&#233;dico. RESULTADOS: La versi&#243;n en portugu&#233;s del MLHFQ se present&#243; con la misma estructura y est&#225;ndares de medici&#243;n de la versi&#243;n original. No hubo dificultad en la aplicaci&#243;n y compensaci&#243;n del cuestionario por parte de los pacientes. La versi&#243;n en portugu&#233;s del MLHFQ result&#243; concordante con el pico de VO2, el tiempo de ejercicio de la prueba de ejercicio cardiopulmonar y con la clasificaci&#243;n funcional de la NYHA. No hubo diferencia del promedio del score del cuestionario entre los grupos de etiolog&#237;a isqu&#233;mica y no isqu&#233;mica. CONCLUSI&#211;N: La versi&#243;n en lengua portuguesa de la MLHFQ, propuesta en el presente estudio, result&#243; v&#225;lida en pacientes con insuficiencia cardiaca, constituyendo un nuevo e importante instrumento para evaluar la calidad de vida.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Insuficiencia cardiaca</kwd>
        <kwd>validaci&#243;n</kwd>
        <kwd>cuestionarios</kwd>
        <kwd>calidad de vida</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p>
        <fn id="top-body2">
          <label>
            <bold>Validaci&#243;n de la versi&#243;n en portugu&#233;s del <italic>Minnesota Living with Heart Failure Questionnaire</italic></bold>
          </label>
          <p>
            <bold>Vitor Oliveira Carvalho; Guilherme Veiga Guimar&#227;es; Dirceu Carrara; Fernando Bacal; Edimar Alcides Bocchi</bold>
          </p>
        </fn>
      </p>
      <p>Laborat&#243;rio de Insufici&#234;ncia Card&#237;aca e Transplante do Instituto do Cora&#231;&#227;o do Hospital das Clinicas da Universidade de S&#227;o Paulo (InCor HCFMUSP), S&#227;o Paulo, SP - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO: </bold> El <italic>Minnesota Living with Heart Failure Questionnaire</italic> (MLHFQ) es un importante instrumento de evaluaci&#243;n de la calidad de vida en pacientes con insuficiencia cardiaca. A pesar de su amplio empleo en nuestro medio, no cont&#225;bamos con su traducci&#243;n y validaci&#243;n en lengua portuguesa.</p>
      <p><bold>OBJETIVO:</bold> Este estudio tuvo por objeto traducir y validar la versi&#243;n en portugu&#233;s del MLHFQ en pacientes con insuficiencia cardiaca.</p>
      <p><bold>M&#201;TODOS:</bold> Se realiz&#243; la prueba de ejercicio cardiopulmonar m&#225;ximo en 40 pacientes con insuficiencia cardiaca (30 varones, FEVE 30&#177;6%, el 55% de etiolog&#237;a isqu&#233;mica, NYHA I a III) con estabilidad cl&#237;nica y terapia medicamentosa optimizada, para evaluarse la capacidad f&#237;sica. Acto seguido, un investigador aplic&#243; el MLHFQ debidamente traducido. La clase funcional NYHA fue referida por el equipo m&#233;dico.</p>
      <p><bold>RESULTADOS:</bold> La versi&#243;n en portugu&#233;s del MLHFQ se present&#243; con la misma estructura y est&#225;ndares de medici&#243;n de la versi&#243;n original. No hubo dificultad en la aplicaci&#243;n y compensaci&#243;n del cuestionario por parte de los pacientes. La versi&#243;n en portugu&#233;s del MLHFQ result&#243; concordante con el pico de VO<sub>2</sub>, el tiempo de ejercicio de la prueba de ejercicio cardiopulmonar y con la clasificaci&#243;n funcional de la NYHA. No hubo diferencia del promedio del score del cuestionario entre los grupos de etiolog&#237;a isqu&#233;mica y no isqu&#233;mica.</p>
      <p><bold>CONCLUSI&#211;N:</bold> La versi&#243;n en lengua portuguesa de la MLHFQ, propuesta en el presente estudio, result&#243; v&#225;lida en pacientes con insuficiencia cardiaca, constituyendo un nuevo e importante instrumento para evaluar la calidad de vida. </p>
      <p><bold>Palabras clave: </bold> Insuficiencia cardiaca, validaci&#243;n, cuestionarios, calidad de vida.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>La insuficiencia cardiaca es la v&#237;a final com&#250;n de toda cardiopat&#237;a y es caracterizada por actividad neurohormonal aumentada, baja tolerancia al ejercicio, baja sobrevida y calidad de vida deteriorada<sup>1-3</sup>.</p>
      <p>La calidad de vida es una discrepancia entre satisfacci&#243;n o descontentamiento con determinadas &#225;reas de la vida, de acuerdo a la percepci&#243;n del propio individuo, y dicha percepci&#243;n es considerada como el mejor indicador de calidad de vida<sup>4</sup>. En el lenguaje convencional, la satisfacci&#243;n con la vida se refiere al cumplimento de necesidades, expectativas, anhelos y deseos<sup>5</sup>.</p>
      <p>Al trabajarse con calidad de vida evaluamos el paciente en las dimensiones &#237;ntima, interactiva, social y f&#237;sica, es decir, como la persona se comporta ante si misma y ante el mundo que la circunda, teniendo en cuenta las relaciones interpersonales y c&#243;mo el mundo en el cual ella vive interfiere en su estado &#237;ntimo, f&#237;sico y social<sup>6</sup>.</p>
      <p>Hay el esfuerzo de la comunidad cient&#237;fica en cuantificar el impacto de la insuficiencia cardiaca en la vida de los pacientes. No obstante la existencia de la clasificaci&#243;n funcional de la <italic>New York Heart Association</italic> (NYHA) y del test de marcha de 6 minutos<sup>7,8</sup>, se cre&#243; el <italic>Minnesota Living with Heart Failure Questionnaire</italic> (MLHFQ) que hoy es ampliamente empleado en nuestro medio y en el mundo. A pesar de ello, no se hab&#237;a llevado a cabo a&#250;n su traducci&#243;n y validaci&#243;n en el Brasil.</p>
      <p>Este estudio tuvo por objeto traducir y validar la versi&#243;n brasile&#241;a del MLHFQ en pacientes con insuficiencia cardiaca.</p>
      <p>
        <bold>M&#233;todos</bold>
      </p>
      <p>
        <bold>Poblaci&#243;n</bold>
      </p>
      <p>Se reclutaron a 40 pacientes de un ambulatorio especializado en insuficiencia cardiaca de un hospital de alta complejidad en cardiolog&#237;a, entre marzo de 2007 y marzo de 2008 (<xref ref-type="table" rid="t1-body2">Tab.1</xref>), todos con insuficiencia cardiaca (30 varones, fracci&#243;n de eyecci&#243;n del ventr&#237;culo izquierdo 30&#177;6%).</p>
      <table-wrap id="t1-body2">
        <graphic xlink:href="1678-4170-abc-93-01-0039-00008-gt01-es.jpg"/></table-wrap>
      <p>Todos los pacientes presentaban estabilidad cl&#237;nica sin alteraciones en las medicaciones y sin per&#237;odos de internaci&#243;n por tres meses. Se excluyeron del estudio a pacientes con otras limitaciones funcionales adem&#225;s de la insuficiencia cardiaca, como osteoartrosis importante, accidente vascular encef&#225;lico y enfermedad pulmonar obstructiva cr&#243;nica.</p>
      <p>Previamente, informamos a los pacientes en cuanto a la finalidad del estudio y se les solicit&#243; la aquiescencia con la firma del formulario de consentimiento informado, aprobado por el Comit&#233; de &#201;tica de la Instituci&#243;n.</p>
      <p>
        <bold>Din&#225;mica del estudio</bold>
      </p>
      <p>En este estudio transversal, todos los pacientes concurrieron en nuestro laboratorio, donde realizaron una prueba de ejercicio cardiopulmonar m&#225;ximo para evaluarse la capacidad f&#237;sica. Seguidamente, un mismo investigador aplic&#243; la versi&#243;n brasile&#241;a del MLHFQ, debidamente traducida, por dos veces, con intervalo de una semana, a fin de preservar la homogeneidad del est&#225;ndar e interpretaci&#243;n de las respuestas alcanzadas y permitir mejor la calidad en la exactitud de los datos obtenidos. El equipo m&#233;dico del ambulatorio responsable del paciente refiri&#243; las clasificaciones funcionales por la NYHA <sup>9</sup>.</p>
      <p>
        <bold>Prueba de ejercicio cardiopulmonar</bold>
      </p>
      <p>Los pacientes fueron orientados a no realizar ninguna actividad f&#237;sica que exija mucho esfuerzo y a no ingerir caf&#233; o alcohol en las 24 horas que antecedieron el examen. La &#250;ltima refecci&#243;n se hizo dos horas antes del examen, como m&#237;nimo. Todos los pacientes realizaron la prueba de ejercicio cardiopulmonar m&#225;ximo (protocolo de Naughton) en una cinta rodante (Series 2000; <italic>Marquette Electronics</italic>; Milwaukee, WI, USA) en una sala con temperatura controlada (21-23&#186;C) entre 10h00 y 15h00 con el registro electrocardiogr&#225;fico de 12 derivaciones (Max 1; <italic>Marquette Electronics</italic>; Milwaukee, WI, USA) y presi&#243;n arterial medida por el m&#233;todo auscultatorio. Ventilaci&#243;n (VE, BTPS), consumo de ox&#237;geno (VO<sub>2</sub>, STPD), gas carb&#243;nico (VCO<sub>2</sub>, STPD) y las otras variables cardiopulmonares fueron adquiridas respiraci&#243;n a respiraci&#243;n por un sistema computarizado (Vm&#225;x 229 model, <italic>SensorMedics</italic>, Yorba Linda, CA, USA). Se tuvo en cuenta el pico del VO<sub>2</sub> como el promedio de los valores finales 30 segundos antes del agotamiento. Un test satisfactorio fue considerado por el cociente respiratorio (R/Q) &gt;1,05 asociado a s&#237;ntomas de esfuerzo m&#225;ximo.</p>
      <p>
        <bold>Traducci&#243;n a la lengua portuguesa del Minnesota Living With Heart Failure Questionnaire</bold>
      </p>
      <p>Se llev&#243; a cabo la traducci&#243;n de acuerdo a algunas etapas propuestas por los coordinadores del IQOLA, y tambi&#233;n con base en trabajos de la literatura que abordan la metodolog&#237;a para la traducci&#243;n de cuestionarios de evaluaci&#243;n de calidad de vida para otras lenguas que no sean la original.</p>
      <p>
        <bold>Traducci&#243;n inicial</bold>
      </p>
      <p>Dos profesores de ingl&#233;s independientes, brasile&#241;os, que conoc&#237;an los objetivos de ese trabajo, tradujeron inicialmente los &#237;tems de la versi&#243;n original del MLHFQ a la lengua portuguesa. En ese momento se enfatiz&#243; sobretodo la traducci&#243;n conceptual y no la estrictamente literaria. Se compararon a las dos traducciones por los propios traductores junto al investigador y, en caso de divergencias, se hicieron los cambios necesarios a fin de obtenerse un consenso en cuanto a la traducci&#243;n inicial (versi&#243;n n&#186; 1 en portugu&#233;s).</p>
      <p>
        <bold>Evaluaci&#243;n de la traducci&#243;n inicial</bold>
      </p>
      <p>Se hizo una traducci&#243;n inversa al ingl&#233;s de la traducci&#243;n inicial por dos profesores de ingl&#233;s, uno de nacionalidad inglesa y el otro, estadounidense, que no participaron de la etapa anterior. Seguidamente, se compararon esas dos versiones con el instrumento original en ingl&#233;s y se documentaron las discrepancias existentes. Un grupo conformado por dos cardi&#243;logos, un enfermero, un psic&#243;logo y uno de los profesores de ingl&#233;s analiz&#243; las versiones. Cuando necesario, las frases en portugu&#233;s fueron reescritas hasta la obtenci&#243;n de un consenso, originando la versi&#243;n n&#186; 2 en portugu&#233;s.</p>
      <p>
        <bold>An&#225;lisis estad&#237;stico</bold>
      </p>
      <p>Los datos fueron analizados con el programa estad&#237;stico SPSS versi&#243;n 11,5 (SPSS Inc., Chicago, IL, USA). El an&#225;lisis descriptivo se present&#243; en promedio y desviaci&#243;n est&#225;ndar. Se emple&#243; el coeficiente de correlaci&#243;n intraclase (r<sub>i</sub>) con el 95% de intervalo de confianza para testar la concordancia de la aplicaci&#243;n y reaplicaci&#243;n del CCVM (Cuestionario sobre Calidad de Vida de Minnesota). Adicionalmente, se llev&#243; a cabo una evaluaci&#243;n visual por medio del gr&#225;fico de Bland &amp; Altman con el l&#237;mite del 95% de concordancia. Se evalu&#243; la consistencia interna de la escala por medio del coeficiente alfa de Cronbach. Se evaluaron por coeficiente de correlaci&#243;n de Spearman la validad del CCVM en comparaci&#243;n al pico VO<sub>2</sub>, tiempo de ejercicio en la prueba de ejercicio cardiopulmonar y la clasificaci&#243;n funcional de la NYHA. La prueba t de Student no pareado se emple&#243; para comparar los promedios del score del CCVM entre los grupos de etiolog&#237;a isqu&#233;mica y no isqu&#233;mica.</p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>Los pacientes incluidos en este estudio presentaron una capacidad f&#237;sica deteriorada (pico de VO<sub>2</sub> menor que 20 mL.Kg.min), un compromiso funcional de la NYHA considerable y un score de la versi&#243;n en portugu&#233;s del MLHFQ (es decir, "Question&#225;rio de Qualidade de Vida de Minnesota-QQVM" en portugu&#233;s, y en espa&#241;ol, Cuestionario sobre Calidad de Vida de Minnesota-CCVM) elevado (<xref ref-type="table" rid="t1-body2">Tab.1</xref>). No hubo cambio en el score del CCVM para el grupo isqu&#233;mico y para el grupo no isqu&#233;mico (53&#177;15 y 42&#177;19, respectivamente; p=0,57; IC= -4.5212 a 27.1640).</p>
      <p>La versi&#243;n en portugu&#233;s del MLHFQ se present&#243; con la misma estructura y dimensi&#243;n de la versi&#243;n original (<xref ref-type="app" rid="es08a01-body2">Anejo 1</xref>). El CCVM se mostr&#243; concordante entre la aplicaci&#243;n y reaplicaci&#243;n del cuestionario (r<sub>i</sub>=0,97; p&lt;0,0001) (<xref ref-type="fig" rid="f1-body2">Figura 1</xref>). El coeficiente alfa de Cronbach fue de 0,97.</p>
      <p content-type="asset"/>
      <fig id="f1-body2">
        <graphic xlink:href="1678-4170-abc-93-01-0039-00008-gf01-es.jpg"/></fig>
      <p>Se observaron correlaciones significativas del score total del CCVM con el pico de VO<sub>2</sub>, el tiempo de ejercicio de la prueba de ejercicio cardiopulmonar y con la clasificaci&#243;n funcional de la NYHA (<xref ref-type="table" rid="t2-body2">Tabla 2</xref>).</p>
      <table-wrap id="t2-body2">
        <graphic xlink:href="1678-4170-abc-93-01-0039-00008-gt02-es.jpg"/></table-wrap>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>El presente estudio efectu&#243; la traducci&#243;n del MLHFQ a la lengua portuguesa. Adem&#225;s de ello, esa versi&#243;n fue concordante con la clasificaci&#243;n funcional de la NYHA, pico de VO<sub>2</sub> y tiempo de ejercicio durante la prueba de ejercicio cardiopulmonar de pacientes con insuficiencia cardiaca. No hubo dificultad en la aplicaci&#243;n de la versi&#243;n en portugu&#233;s del MLHFQ por parte del investigador, ni en el entendimiento del mismo por los pacientes implicados en este estudio.</p>
      <p>El MLHFQ est&#225; conformado por 21 cuestiones relativas a limitaciones que frecuentemente est&#225;n asociadas a la insuficiencia cardiaca como una molestia que impide que los pacientes vivan como les gustar&#237;a. Se debe tener en cuenta el &#250;ltimo mes para responder los cuestionamientos. La escala de respuestas para cada cuesti&#243;n var&#237;a de 0 (no) a 5 (demasiado), donde el 0 representa sin limitaciones y el 5, limitaci&#243;n m&#225;xima. Esas cuestiones implican una dimensi&#243;n f&#237;sica (de 1 a 7, 12 y 13) que est&#225;n altamente interrelacionadas con disnea y fatiga, una dimensi&#243;n emocional (de 17 a 21) y otras cuestiones (de n&#250;mero 8, 9, 10, 11, 14, 15 y 16) que, a&#241;adidas a las dimensiones anteriores, forman el score total. Ese subgrupo de cuestiones, por no presentar un est&#225;ndar usual de respuestas, no fue agrupado como una dimensi&#243;n apartada en el cuestion&#225;rio<sup>10</sup>.</p>
      <p>El MLHFQ se desarroll&#243; espec&#237;ficamente para insuficiencia cardiaca, lo que lo convierte en m&#225;s pr&#243;ximo a la realidad de ese tipo de paciente. Por ello, ese cuestionario puede divergir en algunas cuestiones cuando comparado con otros m&#225;s generales, como el 36-&#237;tem <italic>Short-Form Health Survey</italic> (SF-36) desarrollado para enfermedad cr&#243;nica<sup>11,12</sup>. A pesar de ello, se mostr&#243; una buena concordancia entre el CCVM con el SF-36 en estudio previo, sin embargo ning&#250;n dato de capacidad f&#237;sica fue investigado<sup>12</sup>.</p>
      <p>Se sabe que la clasificaci&#243;n funcional de la NYHA es delimitada por la severidad de los s&#237;ntomas de la insuficiencia cardiaca y, por ese motivo, se esperaba que el MLHFQ fuera &#250;til en el detalle de pacientes con diversos niveles de severidad. No obstante, no se confirm&#243; esa hip&#243;tesis<sup>12</sup>. En nuestro estudio, la clasificaci&#243;n funcional de la NYHA suministrado por el equipo m&#233;dico, as&#237; como el VO<sub>2</sub> de pico y el tiempo de la prueba de ejercicio cardiopulmonar resultaron concordantes con el score del CCVM. Un estudio espa&#241;ol obtuvo una fuerte correlaci&#243;n entre clase funcional de la NYHA con el score de la versi&#243;n espa&#241;ola del MLHFQ, lo que llev&#243; a los autores concluir que el MLHFQ puede reflejar la severidad de la insuficiencia cardiaca<sup>13</sup>. Nuestro estudio obtuvo el mismo resultado. Ese dato nos lleva a imaginar que la versi&#243;n brasile&#241;a del MLHFQ tambi&#233;n puede reflejar la severidad de la insuficiencia cardiaca. A pesar de la etiolog&#237;a presentar un car&#225;cter pron&#243;stico en la insuficiencia cardiaca<sup>14</sup>, no encontramos diferencia en el CCVM entre los grupos de etiolog&#237;a isqu&#233;mica y no isqu&#233;mica.</p>
      <p>Se puede emplear el MLHFQ de forma &#250;nica para acceder la calidad de vida de los pacientes con insuficiencia cardiaca o para evaluar el efecto de una intervenci&#243;n. Por la gran importancia del MLHFQ, varios estudios realizados en el Brasil utilizaron el MLHFQ aun sin su debida traducci&#243;n, validaci&#243;n y publicaci&#243;n. Bocchi et al.<sup>15</sup> estudiaron la calidad de vida por el score de Minnesota en pacientes con insuficiencia cardiaca en tratamiento con levosimend&#225;n. Issa et al.<sup>16</sup> estudiaron el efecto del Bisoprolol en la calidad de vida, y Vilas-Boas et al.<sup>17</sup>, el transplante de c&#233;lulas de medula &#243;sea para el miocardio de pacientes con insuficiencia cardiaca de etiolog&#237;a chag&#225;sica.</p>
      <p>
        <bold>Limitaciones del estudio</bold>
      </p>
      <p>Este estudio fue limitado debido a la no aplicaci&#243;n de un cuestionario sobre calidad de vida validado en el Brasil, como el SF-36. Esa comparaci&#243;n, sin embargo, ya se llev&#243; a cabo previamente<sup>12</sup>.</p>
      <p>
        <bold>Conclusi&#243;n</bold>
      </p>
      <p>La versi&#243;n en lengua portuguesa del MLHFQ, propuesta en el presente estudio, result&#243; v&#225;lida en pacientes con insuficiencia cardiaca, constituyendo un nuevo e importante instrumento para evaluar la calidad de vida y la limitaci&#243;n en la capacidad de realizar actividades de la vida diaria en esa poblaci&#243;n.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio fue parcialmente financiado por la CAPES.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>No hay vinculaci&#243;n de este estudio a programas de postgrado.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
    <back>
      <app-group>
        <app id="es08a01-body2">
          <label>Anejo 1</label>
          <graphic xlink:href="1678-4170-abc-93-01-0039-00008-e01-es.jpg"/></app>
      </app-group>
    </back>
  </sub-article>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Validation of the Portuguese version of the Minnesota Living with Heart Failure Questionnaire</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: The Minnesota Living with Heart Failure Questionnaire (MLHFQ) is an important measurement instrument for assessing the quality of life of heart failure patients. Despite being largely used within our context, the questionnaire had not yet been translated and validated into the Portuguese language. OBJECTIVE: Of this study was to translate and validate the Portuguese version of the MLHFQ for use in heart failure patients. METHODS: Forty patients with heart failure (30 men, LVEF 30&#177;6%, 55% ischemic etiology, classified as NYHA I to III), clinically stable and on optimized drug therapy underwent maximal cardiopulmonary stress testing to assess their physical capacity. Right after the test, the MLHFQ duly translated into Portuguese was administered by the same investigator. The NYHA functional classification was provided by the medical team. RESULTS: The Portuguese version of the MLHFQ had the same structure and metrics of the original version. There was no difficulty in the administration of the questionnaire or in the patient's understanding of the questions. The Portuguese version of the MLHFQ was consistent with peak VO2, duration of the cardiopulmonary test, and NYHA functional classification. There was no difference in the score mean for the questionnaire between the group of patients with ischemic etiology and the group with non-ischemic etiology. CONCLUSION: The Portuguese version of the MLHFQ proposed in this study proved to be valid for heart failure patients, and constitutes a new and important instrument for assessing quality of life.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Heart failure</kwd>
        <kwd>validation</kwd>
        <kwd>questionnaires</kwd>
        <kwd>quality of life</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ORIGINAL ARTICLE</bold>
      </p>
      <p>
        <fn id="top-body3">
          <label>
            <bold>Validation of the Portuguese version of the Minnesota Living with Heart Failure Questionnaire</bold>
          </label>
          <p>
            <bold>Vitor Oliveira Carvalho; Guilherme Veiga Guimar&#227;es; Dirceu Carrara; Fernando Bacal; Edimar Alcides Bocchi</bold>
          </p>
        </fn>
      </p>
      <p>Laborat&#243;rio de Insufici&#234;ncia Card&#237;aca e Transplante do Instituto do Cora&#231;&#227;o do Hospital das Clinicas da Universidade de S&#227;o Paulo (InCor HCFMUSP), S&#227;o Paulo, SP - Brazil</p>
      <p>Mailing address</p>
      <p>
        <bold>SUMMARY</bold>
      </p>
      <p><bold>BACKGROUND: </bold> The Minnesota Living with Heart Failure Questionnaire (MLHFQ) is an important measurement instrument for assessing the quality of life of heart failure patients. Despite being largely used within our context, the questionnaire had not yet been translated and validated into the Portuguese language.</p>
      <p><bold>OBJECTIVE: </bold> Of this study was to translate and validate the Portuguese version of the MLHFQ for use in heart failure patients.</p>
      <p><bold>METHODS: </bold> Forty patients with heart failure (30 men, LVEF 30&#177;6%, 55% ischemic etiology, classified as NYHA I to III), clinically stable and on optimized drug therapy underwent maximal cardiopulmonary stress testing to assess their physical capacity. Right after the test, the MLHFQ duly translated into Portuguese was administered by the same investigator. The NYHA functional classification was provided by the medical team.</p>
      <p><bold>RESULTS: </bold> The Portuguese version of the MLHFQ had the same structure and metrics of the original version. There was no difficulty in the administration of the questionnaire or in the patient's understanding of the questions. The Portuguese version of the MLHFQ was consistent with peak VO<sub>2</sub>, duration of the cardiopulmonary test, and NYHA functional classification. There was no difference in the score mean for the questionnaire between the group of patients with ischemic etiology and the group with non-ischemic etiology.</p>
      <p><bold>CONCLUSION: </bold> The Portuguese version of the MLHFQ proposed in this study proved to be valid for heart failure patients, and constitutes a new and important instrument for assessing quality of life.</p>
      <p><bold>Key words:</bold> Failure; validation; questionnaires; quality of life.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Heart failure, the final common pathway of every heart disease, is characterized by exacerbated neurohormonal activity, low tolerance to exercise, short survival time, and poor quality of life<sup>1-3</sup>.</p>
      <p>Quality of life is a discrepancy between the satisfaction or discontent of an individual regarding certain areas of his/her own life according to his/her own perception, and is considered the best indicator of quality of life<sup>4.</sup> In conventional terms, satisfaction with life refers to the fulfillment of needs, expectations, longings, and desires<sup>5</sup>.</p>
      <p>In dealing with quality of life, we evaluate the aspects of a patient's intimacy, interactions, and social and physical dimensions, i.e., how that person behaves before himself/herself and the world around him/her, taking into consideration interpersonal relationships and how the world interferes in his/her intimate, physical, and social status<sup>6</sup>.</p>
      <p>The scientific community has attempted to quantify the impact of heart failure on patients' lives. Despite the existence of the New York Heart Association (NYHA) functional classification and the Six-minute Walk Test<sup>7,8</sup>, the Minnesota Living with Heart Failure Questionnaire (MLHFQ), was created and is today largely used within our context and worldwide. Nevertheless, the questionnaire had not yet been translated and validated in Brazil.</p>
      <p>This study sought to translate and validate the Portuguese version of the MLHFQ for use in patients with heart failure.</p>
      <p>
        <bold>Methods</bold>
      </p>
      <p>
        <bold>Population</bold>
      </p>
      <p>Forty patients with heart failure (30 men, left ventricular ejection fraction 30&#177;6%) were recruited from an outpatient clinic specialized in heart failure of a high-complexity cardiology hospital, between March 2007 and March 2008 (<xref ref-type="table" rid="t1-body3">Table 1</xref>).</p>
      <table-wrap id="t1-body3">
        <graphic xlink:href="1678-4170-abc-93-01-0039-00008-gt01-en.jpg"/></table-wrap>
      <p>All patients were clinically stable, with no changes in their drug regimen, and had not been hospitalized in the previous three months. Patients with additional functional limitations other than heart failure, such as important osteoarthrosis, cerebrovascular accident, and chronic obstructive pulmonary disease, were excluded from the study.</p>
      <p>All patients were previously informed about the aims of the study and were asked to give their informed consent by signing the appropriate form, approved by the institution's Research in Ethics Committee.</p>
      <p>
        <bold>Dynamics of the study</bold>
      </p>
      <p>In this cross-sectional study, all patients came to our laboratory to undergo a maximal cardiopulmonary stress test in order to evaluate their physical capacity. Right after the test, the Portuguese version of the MLHFQ, duly translated, was applied twice with a one-week interval by the same investigator so as to preserve homogeneity of standards and interpretation of the responses, thus allowing higher accuracy of the data obtained. NYHA functional classifications were provided by the medical team of the outpatient clinic responsible for the patient's care<sup>9</sup>.</p>
      <p>
        <bold>Cardiopulmonary stress testing</bold>
      </p>
      <p>Patients were instructed not to perform any tiring physical activity and not to have coffee or alcohol during the 24 hours preceding the test. The last meal had to be made at least two hours before the test. All patients underwent maximal cardiopulmonary stress testing (Naughton protocol) on a treadmill (Series 2000, Marquette Electronics, Milwaukee, WI, USA) in a room with controlled temperature (21&#186;C to 23&#186;C) between 10:00 a.m. and 3:00 p.m., with a 12-lead electrocardiographic recording (Max 1, Marquette Electronics, Milwaukee, WI, USA) and arterial blood pressure measured by the auscultatory method. Ventilation (LV, BTPS), oxygen consumption (VO<sub>2</sub>, STPD), carbon dioxide (VCO<sub>2</sub>, STPD), and the other cardiopulmonary variables were obtained by breath-by-breath analysis using a computerized system (Vmax 229 model, SensorMedics, Yorba Linda, CA, USA). Peak VO<sub>2</sub> was considered as the mean of the last 30-second values before exhaustion. A test was considered satisfactory when a respiratory quotient (R/Q) &gt;1.05 was associated with symptoms of maximal effort.</p>
      <p>
        <bold>Translation into Portuguese of the Minnesota Living with Heart Failure Questionnaire</bold>
      </p>
      <p>Translation was performed according to a few stages proposed by coordinators of the IQOLA - International Quality of Life Assessment Project,<sup>20</sup> and also based on literature addressing the methodology used for the translation of quality of life evaluation questionnaires into other languages. <sup>20</sup></p>
      <p>
        <bold>The first translation</bold>
      </p>
      <p>The items in the original version of the MLHFQ were initially translated into Portuguese by two independent Brazilian English teachers who were familiar with the goals of the study. At that time, the main focus was on the concepts underlying the document and not on the strictly literary translation. The two translations were then compared by the translators and the investigator; in case of any disagreement, changes were made in order to reach a consensus as to the initial translation (Portuguese Version Number 1).</p>
      <p>
        <bold>Evaluation of the first translation</bold>
      </p>
      <p>The Portuguese Version Number 1 was back-translated into English by two English teachers, one from England and the other one from the United States, who had not participated in the previous phase. Later on, these two versions were compared to the original questionnaire in English, and the existing discrepancies were documented and analyzed by a group consisting of two cardiologists, a nurse, a psychologist, and one of the English teachers. When necessary, the sentences in Portuguese were rewritten until a consensus was reached, thus generating Version Number 2 in Portuguese.</p>
      <p>
        <bold>Statistical analysis</bold>
      </p>
      <p>Data were analyzed using the 11.5 version of the SPSS statistical software (SPSS Inc., Chicago, IL, USA). The Intraclass Correlation Coefficient (r<sub>i</sub>) with 95% confidence interval was used to test the concordance between the MQLQ utilization and re-utilization. Additionally, a visual analysis was carried out through the Bland &amp; Altman plot with a 95% limit of concordance. The internal consistency of the scale was evaluated through Cronbach's alpha coefficient. The validity of the MQLQ in comparison to peak VO<sub>2</sub>, time of exercise at the cardiopulmonary test and the NYHA functional classification was assessed by Spearman's coefficient of correlation. The non-paired Student's <italic>t</italic> test was used to compare the means of the MQLQ score between the groups with ischemic and non-ischemic etiology.</p>
      <p>
        <bold>Results</bold>
      </p>
      <p>Patients included in this study displayed a deteriorated physical capacity (peak VO<sub>2</sub> less than 20 mL/Kg/min), significant functional impairment as measured by the NYHA, and a high score for the Portuguese version of the MLHFQ (i.e., <italic>Question&#225;rio de Qualidade de Vida Minnesota - QQVM</italic>) (<xref ref-type="table" rid="t1-body3">Table 1</xref>). No difference was found for the QQVM score between the ischemic group and the non-ischemic group (53&#177;15 and 42&#177;19, respectively; <italic>p</italic>=0.57; CI = -4.5212 to 27.1640).</p>
      <p>The Portuguese version of the MLHFQ had the same structure and metrics of the original version (Appendix 1). The MQLQ demonstrated concordance between its utilization and re-utilization (r<sub>i</sub>=0.97; p&lt;0.0001) (<xref ref-type="fig" rid="f1-body3">Figure 1</xref>). Cronbach's alpha coefficient was 0.97. Significant correlations were observed between the total MQLQ score and peak VO<sub>2,</sub> time of exercise at the cardiopulmonary test and the NYHA functional classification (<xref ref-type="table" rid="t2-body3">Table 2</xref>).</p>
      <fig id="f1-body3">
        <graphic xlink:href="1678-4170-abc-93-01-0039-00008-gf01-en.jpg"/></fig>
      <table-wrap id="t2-body3">
        <graphic xlink:href="1678-4170-abc-93-01-0039-00008-gt02-en.jpg"/></table-wrap>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>This study did the translation of the MLHFQ into the Portuguese language. Moreover, this version was consistent with the NYHA functional classification, peak VO<sub>2</sub> and duration of physical exercise during the cardiopulmonary stress test in heart failure patients. The investigator had no difficulty in applying the Portuguese version, and the patients had no difficulty understanding it.</p>
      <p>Patients should answer the questions considering the preceding month. The scale of answers to each question ranges from 0 (None) to 5 (Very much), where 0 represents no limitation and 5 represents maximal limitation. These questions involve a physical dimension (from 1 to 7, 12, and 13) which is highly interrelated with dyspnea and fatigue, an emotional dimension (from 17 to 21), and other questions (8, 9, 10, 11, 14, 15, and 16) which added to the previous dimensions, make up the total score. Because this subset of questions does not have a pattern of answers, it was not grouped as a separate dimension in the questionnaire<sup>10</sup>.</p>
      <p>MLHFQ was developed specifically for heart failure, which makes it an instrument much more suited to the reality of this type of patient. For this reason, this questionnaire may differ in some questions when compared to other generic questionnaires such as the 36-item Short-Form Health Survey (SF-36) which was developed for chronic diseases<sup>11,12</sup>. In spite of this, in a prior study good consistency was found between the QQVM and the SF-36, although no one datum for physical capacity was investigated<sup>12</sup>.</p>
      <p>It is known that the NYHA functional classification is characterized by the severity of the heart failure symptoms and, for this reason, MLHFQ was expected to be useful for patients with different degrees of severity. Nevertheless, this hypothesis was not confirmed<sup>12</sup>. In our study, the NYHA classification provided by the medical team, as well as the value of peak VO<sub>2</sub> and the duration of the cardiopulmonary stress test, were consistent with the QQVM score. In a Spanish study, a strong correlation was reported between the NYHA functional classification and the score for the Spanish version of MLHFQ, a fact which led the authors to conclude that MLHFQ may reflect the severity of heart failure<sup>13</sup>. In our study, the result was the same. This finding leads us to think that the Portuguese version of the MLHFQ may also reflect the severity of heart failure. Despite the prognostic nature of the etiology in heart failure<sup>14</sup>, we found no difference in the QQVM between the ischemic and non-ischemic groups.</p>
      <p>MLHFQ can be used in a unique way to assess the quality of life of heart failure patients or to evaluate the outcome of an intervention. Due to its great importance, several studies conducted in Brazil used MLHFQ even before it had been translated, validated, and published. Bocchi et al<sup>15</sup> studied the quality of life of heart failure patients under treatment with Levosimendan using the Minnesota score. Issa et al<sup>16</sup> studied the effect of Bisoprolol on the quality of life, and Vilas-Boas et al<sup>17</sup> analyzed the transplantation of spinal cord cells to the myocardium of patients with chagasic heart failure.</p>
      <p>
        <bold>Limitations of the study</bold>
      </p>
      <p>This study was limited by the non application of a quality of life questionnaire validated in Brazil, such as the SF-36. Nevertheless, this comparison had been made before<sup>12</sup>.</p>
      <p>
        <bold>Conclusion</bold>
      </p>
      <p>The Portuguese version of the MLHFQ proposed in this study proved to be a new valid and important instrument for assessing quality of life and limitations in the capacity of heart failure patients to perform daily activities.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>This study was partially funded by CAPES.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This study is not associated with any post-graduation program.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
</article>
